Markers of epithelial-to-mesenchymal transition reflect tumor biology according to patient age and Gleason score in prostate cancer

Dorota Jędroszka1‡, Magdalena Orzechowska1‡, Raneem Hamouz1, Karolina Górniaık2, Andrzej K. Bednarek1* 

1 Department of Molecular Carcinogenesis, Medical University of Lodz, Lodz, Poland, 2 Department of Pathology, Medical University of Lodz, Lodz, Poland 

‡ These authors are joint first authors on this work. 

* andrzej.bednarek@umed.lodz.pl

Abstract

Introduction

Prostate carcinoma (PRAD) is one of the most frequently diagnosed malignancies amongst men worldwide. It is well-known that androgen receptor (AR) plays a pivotal role in a vast majority of prostate tumors. However, recent evidence emerged stating that estrogen receptors (ERs) may also contribute to prostate tumor development. Moreover, progression and aggressiveness of prostate cancer may be associated with differential expression genes of epithelial-to-mesenchymal transition (EMT). Therefore we aimed to assess the significance of receptors status as well as EMT marker genes expression among PRAD patients in accordance to their age and Gleason score.

Materials and methods

We analyzed TCGA gene expression profiles of 497 prostate tumor samples according to 43 genes involved in EMT and 3 hormone receptor genes (AR, ESR1, ESR2) as well as clinical characteristic of cancer patients. Then patients were divided into four groups according to their age and 5 groups according to Gleason score. Next, we evaluated PRAD samples according to relationship between the set of variables in different combinations and compared differential expression in subsequent groups of patients. The analysis was applied using R packages: FactoMineR, gplots, RColorBrewer and NMF.

Results

MFA analysis resulted in distinct grouping of PRAD patients into four age categories according to expression level of AR, ESR1 and ESR2 with the most distinct group of age less than 50 years old. Further investigations indicated opposite expression profiles of EMT markers between different age groups as well as strong association of EMT gene expression with Gleason score. We found that depending on age of prostate cancer patients and Gleason
score EMT genes with distinctly altered expression are: KRT18, KRT19, MUC1 and COL4A1, CTNNB1, SNAI2, ZEB1 and MMP3.

Conclusions

Our major observation is that prostate cancer from patients under 50 years old compared to older ones has entirely different EMT gene expression profiles showing potentially more aggressive invasive phenotype, despite Gleason score classification.

Introduction

Prostate adenocarcinoma (PRAD) is second the most common solid neoplasm worldwide (incidence rate: 168.3 cases per 100,000 men) [1]. However, there are significant differences in occurrence between regions and country development (70% of accounted PRAD cases are in developed countries). Moreover, increasing age, ethnicity and a family history have been recognized as essential risk factors for PRAD, nevertheless their in-depth significance remains unclear [2].

The current PRAD grading system based on histological expansion rate was developed between 1966 and 1974 by Donald Gleason et al. [3]. Despite scale modifications in 2005 [4] and more recently in 2014 [5] that have dramatically changed original classification, the grading system stays problematic and unclear. In 2013 a new grading system was proposed to minimize overtreatment of low grade prostate tumors detected by PSA tests [6]. Nevertheless, modified Gleason scale remains the golden standard in grading prostate neoplasms. Briefly, according to the guidelines, Gleason score for two the most common patterns is assigned based upon the microscopic appearance of prostate biopsy samples. The more anaplastic and poorly differentiated cells, the higher the Gleason score given, representing a more aggressive character of the tumor. Subsequently, the scores for both patterns are summed to obtain eventual Gleason score ranging from 2–10 (well-differentiated to least differentiated) thus representing biologically similar groups of low, intermediate and high-grades [7].

Epithelial-to-mesenchymal transition (EMT) is a basic mechanism that plays a central role in development, tissue regeneration, architecture and remodeling in physiology as well as pathological migratory properties of cancer cells. In greater detail, EMT describes a process of loss of epithelial character towards gain of mesenchymal properties. This is done mainly due to loss of cell-cell communication, adhesion and reorganization of cytoskeleton leading to a switch from apical-basal to front-rear polarity of cells. Therefore, the EMT may be considered as molecular mechanism of acquisition of invasive properties as well as enhancing tumor aggressiveness and migratory potential through involvement of regulatory pathways (mainly transforming growth factor β (TGF-β), phosphatidylinositol-3-kinase (PI3K) and mitogen-associated protein kinase (MAPK)) and particular genes (E-cadherin, β-catenin, fibronectin, vimentin and matrix metalloproteases) [8]. In fact, since Gleason score quasi represents the tumor aggressiveness it becomes apparent that Gleason may be considered as morphological evidence of EMT and has been hereby described [9]. Many recent studies have focused on in vivo significance of EMT with respect to clinical course of the disease, however there are still some discrepancies, which should be investigated [10].

The association between patient age and aggressiveness (and hence Gleason score) of prostate tumor has not been well investigated so far. There are many reports suggesting that younger men experience PRAD of completely different biology compared to those diagnosed at
higher age [11]. This raises several important questions how to distinguish aggressive cases from indolent form and regarding the management adjusted to the differential biology of the tumor.

Signaling via androgen receptor (AR) plays a pivotal role in both, the development and function of normal prostate gland as well as tumorigenesis of the prostate. Canonical signaling through AR comprises modulation of transcriptional activity of particular genes through AR nuclear translocation and binding to androgen response elements (AREs) on its targets followed by recruitment or crosstalk with various transcription factors (TFs)[12]. Surprisingly, recent works have started to prove that not only AR has major influence on predisposing and a PRAD incident, but so do estrogen receptors. Especially, the role of ESR2 is believed to be important in prostate cancer progression. Nevertheless, their significance in PRAD biology and in accordance to patient age remains inconclusive [13].

To date, several studies indicated that sex hormones such as testosterone and estradiol are declining with age in males. More particularly, androgen levels and estrogen levels are unbalanced in men of higher age, it has been showed that androgen loses its significance in favor of estrogen followed by altered body composition and increased BMI in olders [14].

Considering the fact that the levels of androgens and estrogens in men change with age and taking into account the impact of estrogen and androgen hormones in PRAD progression and development, we have studied biological differences of PRAD between younger and older patients. Moreover, we also examined the significance of EMT and signaling via AR and both ERs status in prostate according to patient age and Gleason score.

Results

The significance of hormone receptors changes with patient’s age

Firstly, we examined the significance of three hormone receptors: AR, ESR1, ESR2 in the biology of prostate cancer regarding the effect of their expression on tumor recurrence according to patient’s age (four age groups: ≤50, 51–60, 61–70, 70+ years old) through disease-free survival (DFS) analysis. We found a shift in the significance of the receptors for tumor recurrence; higher rates of AR expression are unfavorable for prostate tumor in younger patients, however it loses its significance in the oldest group, in contrast to ESR1, where higher expression is generally unfavorable. In greater detail, we identified lowered expression of AR as favorable in groups of ≤50 and 51–60 years old (HR > 100, p = 0.036; HR = 3.12, p = 0.0027, respectively), whereas in groups of older patients (61–70 and 70+ years old) AR lost its significance. In contrast, ESR1 did not show any importance in groups of ≤50 and 70+ years old in tumor recurrence, although its lowered expression was associated with better prognosis in remaining groups of 51–60 and 61–70 years old (HR = 7.95, p < 0.001; HR = 2.75, p = 0.0053). Finally, lowered expression of ESR2 correlated with good prognosis in group of 51–60 years old (HR = 2.36, p = 0.033), whereas relatively higher expression was favorable in group of 61–70 years old (HR = 0.31, p = 0.024) while not relevant in the youngest and oldest patients. Summarized results are presented in Table 1. Full results of DFS analysis with Kaplan-Meier plots are enclosed as S1 Fig.

Subsequently, we focused on biological differences between prostate tumors regarding sets of variables such as patient age, Gleason score as well as hormone receptors expression. Patients were dimensionally partitioned by applying the Multiple Factor Analysis (MFA).

First analytical variant comprised combined expression of AR, ESR1 and ESR2, patient age and Gleason score as supplementary variable. The analysis resulted in plots of individuals (patients) shown as Fig 1 with 39.52% of the total variability for the first two dimensions. We observed clearly distinct grouping of patients aged ≤50 and 70+ years old and more common
Table 1. DFS analysis shows differences in tumor biology according to patient age.

| Gene | ≤50  | 51–60 | 61–70 | 70+ |
|------|------|-------|-------|-----|
|      | Age group | Number of patients in group | HR<sup>1</sup> | Number of patients in group | HR<sup>1</sup> | Number of patients in group | HR<sup>1</sup> | Number of patients in group | HR<sup>1</sup> |
|      | Low expression<sup>2</sup> | High expression<sup>2</sup> | Low expression<sup>2</sup> | High expression<sup>2</sup> | Low expression<sup>2</sup> | High expression<sup>2</sup> | Low expression<sup>2</sup> | High expression<sup>2</sup> | Low expression<sup>2</sup> | High expression<sup>2</sup> |
| AR   | >100* | 12 | 23 | 3.12* | 95 | 93 | 1.77 | 136 | 101 | 0.28 | 17 | 20 |
| ESR1 | 0.24 | 11 | 24 | 7.95** | 176 | 12 | 2.75* | 213 | 24 | 2.12 | 12 | 25 |
| ESR2 | >100 | 11 | 24 | 2.36* | 165 | 23 | 0.31* | 17 | 220 | 0.15 | 21 | 16 |

<sup>1</sup>Hazard ratio.

<sup>2</sup>“Low expression” is defined as expression values below the cutoff and “high expression” as expression values above the cutoff.

* p-value < 0.05,

** p-value < 0.001

https://doi.org/10.1371/journal.pone.0188842.t001
character of tumors in patients aged 51–70 years old. More specifically, the contribution of all three hormone receptors are pretty similar in the prostate tumorigenesis, however the shift in the significance from androgen in the youngest towards estrogen alpha in the oldest group may be observed in the projections along Dim1 and Dim2 (Fig 1C), while the distribution of Gleason score in the groups remains equable (Fig 1A and 1B). Additionally, as we pointed out higher expression of ESR1 was unfavorable for tumor recurrence, thus it may indicate that the shift from a high AR expression in patients aged ≤50 years old towards high expression of ESR1 in patients aged 70+ years old is caused by the occurrence of andropause in the oldest group (Fig 1D). This finding has been referred to expression rates of hormone receptors in matched, normal adjacent samples. Admittedly, the group sizes were much smaller (<50: 5, 51–60: 18, 61–70: 25, 70+: 4 normal samples vs ≤50: 35, 51–60: 188, 61–70: 237, 70+: 37 tumor samples), but we found significant changes in expression of hormone receptors: lower expression of AR in groups ≤50 and 70+ years old and its higher expression in groups 51–70,
although no visible changes in both estrogen receptors, possibly indicating that tumors in older patients result from hyperplasia of the prostate and seem to be more normal-like (Fig 1E).

Prostate tumor aggressiveness is reflected by EMT profile due to different mechanism of transition in younger males

Next, as we identified different profiles of hormone receptors in the youngest vs the oldest patients we investigated further biological effects possibly explaining the aggressive course of the disease in men aged ≤50 years in contrast to the oldest males. Therefore we focused on the mechanism of EMT (which is directly associated with cancer aggressiveness and thus indirectly with Gleason score) through the insight into expression of EMT marker genes in correlation with patients age and Gleason score. Primarily, we selected from the literature 43 well-known EMT markers (Table 2). Subsequently, we applied MFA according to expression of all 43 EMT markers, age groups with Gleason score (supplementary variable) and found distinct profiles of EMT genes in patients aged ≤50 years associated with different response to hormone signaling, with no visible patterns of Gleason distribution (S2A and S2B Fig). In addition, hierarchical clustering of EMT markers according to patients age revealed apparently different character of the tumors diagnosed at age ≤50 years with overexpression of CTNNB1, SMAD2, SMAD3, TCF4 and ZEB1 indicating more aggressive clinical course of the tumor due to predominance of mesenchymal pattern in the youngest males (S2D Fig).

Furthermore, from the initial 43 EMT markers we subsequently focused on the 31 genes (hereinafter called as selected), which were mostly differentiating patients ≤50 vs 70+ years old. As can be seen in the Fig 2, by applying MFA the youngest patients were even more distinct with 31.26% of the total variability, while the distribution of Gleason score remained equitable. The heatmap representing contrasting profiles of selected EMT markers in patients according to age group may be seen in the Fig 3.

Subsequently we evaluated epithelial apart from mesenchymal state markers and their separate contribution to biology of the tumors in respect to patients age as well as dimensional partitioning of PRAD cases. The variant considering all divided EMT markers enabled us to identify two phenomena: first, reversed profiles between epithelial and mesenchymal states especially in groups of ≤50 and 70+ years old (S3A and S3B Fig) and second, significant shift in projections along Dim2 between the youngest and the oldest groups of patients (S3C and S3D Fig). Therefore, differential expression of EMT genes shows shift towards more mesenchymal and thus more aggressive phenotype of tumors in patients ≤50 years old (S3E and S3F Fig). Similar partitioning was found in markers after selection of the most differentiating genes with slight shift in epithelial markers regarding group aged ≤50 years old (Fig 4).

Profile of EMT markers reflects Gleason score

Furthermore, as EMT signature has been found significantly contrasting PRAD patients according their age and tumor biology, we evaluated the association of Gleason score and EMT markers (which a priori should be true). As expected, we found that expression of selected EMT markers pretty well differentiates Gleason scores into separate partitions along with the dimensions with 29.03% of total variability, thus bearing out the strong relationship between tumor aggressiveness characterized on the one hand by expression of EMT markers and on the other, by clinical parameter—Gleason score (Fig 5A). Noteworthy, as shown in the Fig 5B, the expression of particular genes involved in EMT changes along with higher Gleason scores, hence represents increase in aggressiveness of prostate tumor.
We performed validation of hierarchical clustering analysis regarding expression of EMT marker genes in association with Gleason score. Our results validation was performed on Table 2. List of genes involved in epithelial-to-mesenchymal transition (based on literature review).

| Gene symbol | Gene name                                | Marker of                  | References |
|-------------|------------------------------------------|----------------------------|------------|
| CDH1        | Cadherin 1, E-cadherin                   | epithelial state           | [15–17]    |
| COL4A1      | Collagen type IV alpha 1 chain           |                            |            |
| DSP         | Desmoplakin                              |                            |            |
| KRT18       | Keratin 18                               |                            |            |
| KRT19       | Keratin 19                               |                            |            |
| KRT5        | Keratin 5                                |                            |            |
| LAMA1       | Laminin subunit alpha 1                 |                            |            |
| LAMA2       | Laminin subunit alpha 2                 |                            |            |
| LAMA3       | Laminin subunit alpha 3                 |                            |            |
| LAMA4       | Laminin subunit alpha 4                 |                            |            |
| LAMA5       | Laminin subunit alpha 5                 |                            |            |
| MUC1        | Mucin 1, cell surface assoc.             |                            |            |
| NID1        | Nidogen 1                                |                            |            |
| OCLN        | Occludin                                 |                            |            |
| TJP1        | Tight junction protein 1                |                            |            |
| ACTA2       | Actin 2, alpha 2                         | mesenchymal state          |            |
| CDH11       | Cadherin 11                              |                            |            |
| CDH2        | Cadherin 2, N-cadherin                  |                            |            |
| CTNNB1      | Catenin beta 1                           |                            |            |
| DDR2        | Discoidin domain receptor tyrosine kinase 2 |                      |            |
| FN1         | Fibronectin 1                            |                            |            |
| FOXC2       | Forkhead box C2                         |                            |            |
| GSC         | Goosecoid homeobox                       |                            |            |
| ITGA5       | Integrin subunit alpha 5                |                            |            |
| ITGB6       | Integrin subunit beta 6                 |                            |            |
| KRT8        | Keratin 8                                |                            |            |
| LEF1        | Lymphoid enhancer binding factor 1       |                            |            |
| MMP2        | Matrix metallopeptidase 2                |                            |            |
| MMP3        | Matrix metallopeptidase 3                |                            |            |
| MMP9        | Matrix metallopeptidase 9                |                            |            |
| S100A4      | S100 calcium binding protein A4          |                            |            |
| SDC1        | Syndecan 1                               |                            |            |
| SERPINF1    | Serpin family H member 1                |                            |            |
| SMAD2       | SMAD family member 2                     |                            |            |
| SMAD3       | SMAD family member 3                     |                            |            |
| SNAI1       | Snail family transcriptional repressor 1 |                            |            |
| SNAI2       | Snail family transcriptional repressor 2 |                            |            |
| TCF3        | Transcription factor 3                   |                            |            |
| TCF4        | Transcription factor 4                   |                            |            |
| TWIST1      | Twist family bHLH transcription factor 1  |                            |            |
| VIM         | vimentin                                 |                            |            |
| ZEB1        | Zinc finger E-box binding homeobox 1     |                            |            |
| ZEB2        | Zinc finger E-box binding homeobox 2     |                            |            |

https://doi.org/10.1371/journal.pone.0188842.t002

**Validation test**

We performed validation of hierarchical clustering analysis regarding expression of EMT marker genes in association with Gleason score. Our results validation was performed on
mRNA expression data from Prostate Adenocarcinoma (MSKCC, Cancer Cell 2010) cohort from cBioportal due to the sufficient number of patients and available information of Gleason score. Those gene expression data comes from different cohort of patients and were obtained using microarray analysis. Although patients with Gleason 10 are missing, this analysis confirmed general tendency that profiles of EMT markers are distinct among Gleason score especially in patient with high Gleason score (S4 Fig). Several mesenchymal markers like SNAI1 and its target genes MMP3 and MMP9 are elevated while crucial epithelial markers CDH1, KRT5 and KRT19 are significantly decreased.

Fig 2. Distinct biology of PRAD patients aged ≤50 years old relates to different profile of EMT. The expression of selected EMT markers indicates completely different partitioning of PRAD patients aged ≤50 years old (A), however equable distribution of Gleason score amongst patients (B). The projections along Dim2 show distinct grouping of patients aged ≤50 years old in association with different profile of selected EMT markers with simultaneous similar character of tumor diagnosed in older males (C).
Common Gleason score, but different molecular profiles of EMT markers according to age group

We demonstrate the expression profiles of all EMT markers in higher Gleason score groups (the most aggressive cases: 8+9 with exception of Gleason 10 due to insufficient number of patients) according to patients age. We observed that the same Gleason score differs in the EMT signature according to patient age. In particular, we found primarily overexpression of \(\text{CTNNB1} \), \(\text{CDH1} \), \(\text{SMAD2} \), \(\text{SMAD3} \), \(\text{TCF3} \), \(\text{LEF1} \) in younger patients and overexpression of \(\text{SNAI1} \) and underexpression of \(\text{KRT5} \), \(\text{KRT19} \), \(\text{OCLN} \), \(\text{CDH2} \) and \(\text{MUC1} \) which clearly indicates different characteristics of prostate tumor in younger vs older patients (Fig 6).

Mutations play marginal role in prostate tumorigenesis

Cancer has been recently considered as genetic disorder, which results from many alterations at molecular level with mutations among others. To complete the insight into prostate tumorigenesis biology we additionally examined the significance of the mutations borne by patients, although their role seems marginal (does not exceed 20% of all cases). Tables 3 and 4 present mutational reports from COSMIC database vs mutations identified within PRAD cohort. Most mutations in PRAD affect \(\text{TP53} \) gene, as we should suspect. Second in mutation rate is androgen receptor, the castrate resistant cancer, thought there is less than 10% mutations found in COSMIC reported prostate cancer. Therefore, as in the most sporadic cancers there is no specific highly represented mutations in PRAD. Nevertheless, in the era of personalized medicine, even relatively rare mutations can be important in treatment profiling.

Discussion

Role of androgen and estrogen receptors

In our study we aimed to evaluate DFS prognostic effect of androgen and estrogen receptors gene expression according to patient age in prostate cancer. Multifaceted association of
Fig 4. Prostate tumors diagnosed at age ≤50 and >70 years old show a shift in characteristics regarding expression of the mostly differentiating epithelial vs mesenchymal state markers. The expression of epithelial (A, C) vs mesenchymal (B, D) state markers in separate partitions PRAD patients oppositely. The projections representing contribution of epithelial (E) and mesenchymal (F) state markers along the dimensions indicate significant shift in the EMT model in the age groups, especially in the youngest and the oldest males. In addition, the shift towards more aggressive mesenchymal character of the tumor is observable in the contrasting expression of particular genes involved in the EMT (G) epithelial state markers, H) mesenchymal state markers).

https://doi.org/10.1371/journal.pone.0188842.g004
receptors gene expression with DFS inclined us to explore biological and clinical differences between age groups of patients with prostate adenocarcinoma. For this purpose we analyzed epithelial to mesenchymal transition marker genes which are responsible for cancer cell aggressiveness, metastasis and poor prognosis in various tumors. We performed multiple factor analysis to integrate the relationship between the groups of variables (age, Gleason score and genes expression) describing the individuals (patients). Our results showed that

Fig 5. Expression of EMT markers differentiates well Gleason score. A) Combined expression of selected EMT markers partitions Gleason score along the PCA dimensions. B) Expression of particular EMT markers changes with Gleason score.

https://doi.org/10.1371/journal.pone.0188842.g005

Profiles of EMT characterize prostate cancer biology
Fig 6. The same Gleason score differs in age groups in expression of EMT markers. The profiles of EMT markers are distinct between age groups within the same Gleason score (A). Differential expression of epithelial (B) vs mesenchymal (C) markers in age groups within the same Gleason score.

https://doi.org/10.1371/journal.pone.0188842.g006
### Table 3. Top 20 mutations reported by COSMIC database vs PRAD cohort.

| Gene symbol | COSMIC no. | COSMIC % | TCGA no. | TCGA % |
|-------------|------------|-----------|----------|--------|
| TP53        | 2506       | 15        | 497      | 12.2   |
| AR          | 2992       | 9         |          | 0.6    |
| SPOP        | 1802       | 8         |          | 11.4   |
| PTEN        | 2339       | 7         |          | 3.4    |
| KMT2C       | 1436       | 5         |          | 6      |
| KMT2D       | 1438       | 5         |          | 5.8    |
| FOXA1       | 1670       | 5         |          | 5.6    |
| FAT4        | 1436       | 5         |          | 2.4    |
| LRP1B       | 1436       | 4         |          | 4.8    |
| KRAS        | 2831       | 3         |          | 0.4    |
| ATM         | 1503       | 3         |          | 4.4    |
| ZFHX3       | 1436       | 3         |          | 3.2    |
| CTNNB1      | 1958       | 3         |          | 2.6    |
| APC         | 1676       | 3         |          | 2      |
| EGFR        | 2083       | 2         |          | 0.6    |
| PIK3CA      | 1944       | 2         |          | 2.8    |
| SPEN        | 1462       | 2         |          | 1.4    |
| FAT1        | 1436       | 2         |          | 0.8    |
| GRIN2A      | 1444       | 2         |          | 2.2    |
| BRCA2       | 1603       | 2         |          | 1.8    |

https://doi.org/10.1371/journal.pone.0188842.t003

### Table 4. Top 20 mutations identified within PRAD cohort.

| Gene symbol | TCGA no. | TCGA % |
|-------------|----------|--------|
| FRG1BP      | 97       | 19.4   |
| TP53        | 61       | 12.2   |
| SPOP        | 57       | 11.4   |
| MUC17       | 33       | 6.6    |
| KMT2C       | 30       | 6      |
| KMT2D       | 29       | 5.8    |
| FOXA1       | 28       | 5.6    |
| NBPF1       | 27       | 5.4    |
| SYNE1       | 27       | 5.4    |
| SPTA1       | 26       | 5.2    |
| LRP1B       | 24       | 4.8    |
| KRTP4-11    | 24       | 4.8    |
| NBPF10      | 23       | 4.6    |
| ATM         | 22       | 4.4    |
| ZAN         | 22       | 4.4    |
| CHEK2       | 21       | 4.2    |
| FAT3        | 19       | 3.8    |
| OBSCN       | 18       | 3.6    |
| RGPD8       | 18       | 3.6    |
| PTEN        | 17       | 3.4    |

https://doi.org/10.1371/journal.pone.0188842.t004
accordingly to patient age, gene expression and Gleason score, the most diverse group form patients below 50 years old.

Androgen signaling is the key regulator in normal development and maintenance of the prostate growth and function. There is a growing body of evidence supporting involvement of the androgen receptor in the progression of hormone-sensitive but also hormone-insensitive prostate cancer. Moreover, the majority of prostate cancer both at primary and metastatic sites are characterized by AR presence regardless of stage and grade. Zegarra-Moro et al. demonstrated that AR is critical for development and proliferation of androgen-refractory prostate tumor cell lines LNCaP-Rf and LNCaP-C4 [18]. AR overexpression and amplification in prostate cancer cells has been shown to correlate with lower recurrence-free survival rates [19] as well as the transition from hormone sensitive to resistant prostate tumor [20,21]. Patients with high levels of AR in malignant epithelial cells and a reduction of AR positive nuclear in peritumoral stromal cells had increased risk of relapse following radical prostatectomy [22]. Consistent with the earlier reports, our analysis has shown that AR decreased expression is significantly associated with better DFS prognosis but only for relatively young patients below 50 years old and for the age group 51–60. Moreover, for patients under 50 years old, AR expression profile points to unfavorable prognosis due to the fact that in this group AR expression is upregulated in comparison to normal adjacent tissue (Fig 1D and 1E). This could mean that through the high AR level and different expression profile of AR compared to favorable prognosis, younger patients have even more aggressive type of cancer than patients in more advanced age.

In addition to role of androgens in prostate carcinogenesis, estrogen and thus estrogen receptors play an important role in molecular mechanism of tumorigenesis through proliferation, apoptosis, invasiveness or epithelial-to-mesenchymal transition (EMT)[23–26]. In prostate ERα is mainly expressed in stromal cells, whereas ERβ is localized mainly in epithelial cells [27,28]. Studies have shown the oncogenic role of ERα in various prostate cancer cell lines including PacMetUT1, C4-2, 22Rv1 and LNCaP [27] but also in patients with aggressive high Gleason score tumors [28]. Moreover, ERα has been found to mediate bone and lung metastasis and induce EMT program in cancer cells [27]. Gene polymorphisms in the ERα and ERβ locus have been shown to be significantly associated with prostate cancer risk, overall or by grade, and stage [29]. Studies on animal model (ER-knockout, ERKO mice) show that ERβ-knockout mice develop prostate cancer after stimulation of testosterone or other sex hormones, whereas ERα KO do not [30]. Furthermore, Leav et al. demonstrated diminished expression of ERβ during prostatic carcinogenesis and tumor progression [31]. Our analysis showed, for the first time, that for patients older than 50 years old, lowered expression of ERα in prostate cancer cells indicates better prognosis, which would coincide with its oncogenic character. On the other hand, we observed an association of favorable DFS prognosis with ERβ decreased expression in younger group of patients, whereas in patients older than 60 years old decreased ERβ expression indicates bad prognosis. Together our data would seem to suggest that ERα may play an oncogenic role for patient age above 50. In this context it is worth to mention that estrogen receptors may have significant influence on prostate cancer aggressiveness especially in patients older than 70 years old. Decreased level of ERα and increased level of ERβ are correlated with better prognosis for older patients while in younger groups of patients better DFS prognosis is associated with opposite expression profiles of hormone receptor genes (S1 Fig). Moreover the attention should be paid to fact that according to MFA analysis, gene expression of sex hormone receptors is very similar during disease progression (Fig 1C), however there is a visible change in gene expression dominance from AR in younger patients to ESR1 and ESR2 in older patients (Fig 1D).
We also investigated the mechanism of epithelial-to-mesenchymal transition and have looked into differences in the expression of EMT genes according to patient age and Gleason score. Since it is well known that Gleason score is a clinical representation of aggressiveness, it should be a direct association between Gleason grade and EMT transition. And it is in fact, that that Gleason grades are clearly separated from the other according to the EMT genes, with Gleason 10 as the most distant phenotype (individual factor map, Fig 5A). Moreover, the expression of specific EMT genes change along with higher Gleason score (Fig 5B). Finding that there is a switch between the androgen and estrogen receptors gene expression depending on the patient age, as well as Gleason score association with EMT we assumed that there may be some distinct differences between younger and older patients in the profile of epithelial to mesenchymal transition mechanism in prostate cancer progression.

### Epithelial-to-mesenchymal transition in prostate cancer

Epithelial-to-mesenchymal transition is a biological process in which loss of epithelial cell phenotype leads to destabilization of intercellular interaction and cell polarity. Therefore inducing tissue disintegration. One of the major changes is loss of E-cadherin in cellular membrane. At the same time due to gain of expression of genes like vimentin and N-cadherin, cells acquire mesenchymal phenotype facilitating migration, invasion and survival in an anchorage-independent environment. EMT is observed under physiological condition because it underlies many phases of embryonic development. However it may occur in many pathological states such as tumorigenesis and metastasis [15,32,33]. Its relevance in cancer progression has been demonstrated in the context of direct repression of E-cadherin promotor by group of transcription factor from SNAIL, TWIST and ZEB families [34,35]. E-cadherin plays an important role in maintenance the epithelial integrity [36] and its decreasing is well described in many cancers. In prostate cancer aberrant expression of E-cadherin is characteristic for high-grade tumor [37] and associated with poor overall survival of patients [38]. Our analysis shown that expression of CDH1 was actually reduced in prostate tumors from patients older than 50 years old (Fig 3). Interestingly, that in group of prostate cancer patients under the age of 50, E-cadherin expression is greatly enhanced in tumors together with the overexpression of β-catenin gene. In normal cells CTNNB1 forms a complex with CDH1 and stabilizes cell to cell adhesion [32,39]. However, as a result of aberrant activation of Wnt/β-catenin pathway in the cancer, cytoplasmic accumulation of β-catenin and proliferation of prostatic cells were observed [40–42]. It may be possible that due to enhanced activity of strongly oncogenic Wnt pathway and the relatively high expression, E-cadherin loses its normal function. Moreover, the oncogenic effect of CTNNB1 may be further enhanced by the synergistic activity of SMADs, TCF and LEF (Figs 4E and 6C) that was also confirmed in Labbe et al. study that shown that activities of these genes products strongly induce target genes transcription at when all three transcription factors are involved [43]. Another proposed hypothesis says that along with the progress of EMT, the neoplastic cells regain CDH1 expression in established metastatic foci [44]. Re-acquisition of cell-cell adhesion ability typical for epithelial phenotype could be advantageous for tumor growth and escalated invasiveness. Saha et al. found overexpression of both adhesion-associated proteins in metastatic cancer cells and their reduced expression in primary prostate cancer cells [45]. In contrast, we observed that relatively high CDH1 expression in primary tumors from younger patients is associated with higher Gleason score characteristic for local invasiveness. Our analysis (Fig 6B and 6C) show that younger patient cancers with Gleason score equal 8 and 9 are characterized by significant overexpression both of CDH1 and CTNNB1 (Fig 6B and 6C). On the other hand decreased expression of these two genes are observed for patients above the age of 50 also when Gleason score is high. Furthermore, older...
patients, especially over the age of 70, are characterized by increased level of CDH2 expression (Fig 6C). It may reflect a phenomenon called “cadherin switch” during which loss of epithelial E-cadherin is accompanied by production of mesenchymal N-cadherin [46–48]. CDH2 is typically expressed in mesenchymal cells and its upregulation in cancer promotes cell motility and invasiveness [49]. In prostate cancer, the switch between E-cadherin and N-cadherin was reported for high Gleason grade tumors [50]. This data suggest that according to patient age increased or decreased level of CDH1 and CTNNB1 has a significant influence on the aggressiveness of the tumor and is associated with different profiles of epithelial-mesenchymal transitions.

Recently, upregulation of several E-cadherin transcriptional repressors like Snail, Twist and Zeb families was found to be crucial for repressing the E-cadherin and thus redirecting cells toward mesenchymal phenotype [34]. ZEB1 overexpression is associated with tumor cells migration and invasion and together with inhibition of E-cadherin gene expression mediates progression to metastasis [51]. A recent report demonstrated that high ZEB1 expression directly correlates with high Gleason grade prostate adenocarcinoma [52,53] that is also demonstrated by our analysis (Fig 5B). Alike ZEB1 also SNAI1 and SNAI2 are strongly associated with high Gleason score 10 (Fig 5B), indicating them as markers of an aggressive and advanced prostate cancer phenotype. On the other hand, we observed ZEB1 decreased expression in tumors of Gleason score 8 and 9 from patients groups aged under 50 and over 70 years. Using in vitro model Drake et al. established for TEM4-18 prostate cancer cells which underwent EMT, loss of ZEB1 leads to upregulation of epithelial marker CDH1, enabling gain of epithelial character [51]. Together with our analysis this suggests that younger patients have even more advanced subtype of prostate cancer; in terms of aggressiveness due to the enhanced E-cadherin (together with β-catenin) level leading to more metastatic phenotype. On the other hand, for older patients low expression of ZEB1 could be compensated by other EMT regulator such as SNAI1 (Fig 6C). For example, several studies demonstrated that SNAI1 is a master regulator sufficient for induction of EMT [54,55]. Additionally SNAI1 is crucial for expression regulation of epithelial genes such as KRT18, OCLN and MUC1 [56], as well as enhanced expression of mesenchymal markers such as VIM, MMP2, -9 [57]. Our investigation supports this findings due to the fact that along with the elevated level of SNAI1 there is significant loss of KRT5, KRT19, OCLN, CDH1, MUC1 and several other epithelial marker genes in patients older than 70 years with Gleason score 8 and 9. Similarly, expression of KRT18, CDH1 and OCLN are decreased in younger patients (of the age group 61–70 years old) but at the same time much more mesenchymal markers which are targets of SNAI1 are increased (MMP2, MMP3, MMP9, ZEB1, ZEB2) (Fig 6B and 6C).

Metalloproteases are important factors involved in degradation of extracellular matrix and basement membrane thus contribute to the alteration of cell-matrix adhesion [58,59]. Compiling all data it is becoming evident that according to age, patients with prostate cancer have various mechanism of epithelial to mesenchymal transition. This agrees with clinical data showing that prostate cancer in younger patients is different than in older in a view of survival rate. Specifically, Lin et al. observed that among all men with high grade tumor or locally advanced cancer at diagnosis, younger males had significantly decreased overall survival and disease specific survival [60]. Moreover, Merrill and Bird found that among males diagnosed with advanced or unknown stage or grade prostate cancer, the youngest (<50 y.o.) and the oldest (>80 y.o.) patients were characterized by the poorest prognosis [61]. There are also some new evidences that males aged under 50 years had similar pathological tumor characteristic, histological grade, disease stage, PSA level and biochemical free survival compared to the older population [62,63]. Our finding shows fundamental molecular differences between prostate cancers form young and old patients. The most distinct group according to switch in
epithelial-mesenchymal profile seems to be group of patients younger than 50 years old. In this group crucial transcription regulators \textit{ZEB1} and \textit{SNAI1} as well as many mesenchymal markers like \textit{VIM}, \textit{CDH2}, \textit{MMP2}, \textit{MMP3}, \textit{MMP9} are downregulated. But at the same time these patients are characterized by overexpression of the adhesion proteins \textit{CDH1} and \textit{CTNNB1} which according to the literature could be advantageous for invasiveness and colonization. On the other hand, reversed profiles of epithelial and mesenchymal markers could be seen in older prostate cancer patients. In cancers from patients older than 70 years more significant seems to be the upregulation of key transcription factor \textit{SNAI1} and decreased expression of genes responsible for epithelial phenotype \textit{KRT19}, \textit{CDH1}, \textit{OCLN} and \textit{MUC1}. Summarizing, our analysis shows distinct and biologically significant differences in expression profile of sex hormone receptors as well as epithelial to mesenchymal transition genes that are associated with disease progression depicted as Gleason score. However, despite of Gleason score, distinct profiles of EMT genes expression may explain more aggressive phenotype of prostate cancer in younger patients.

\textbf{Materials and methods}

We performed The Cancer Genome Atlas (TCGA) RNA-Seq expression profiling (level 3 RNASeqV2, RSEM normalized) and clinical characteristics of 499 PRAD patients (http://cancergenome.nih.gov/, data status of Jan 28, 2016). The methods of biospecimen procurement, RNA isolation and RNA sequencing were previously described by The Cancer Genome Atlas Research Network [64].

Afterwards, we combined RNA-Seq data with patient clinical outcome. Samples with any missing clinical or expression values were excluded from further considerations. Finally, we qualified a total of 497 samples.

To determine the relevance of patient age and its associations with hormone receptors (\textit{AR}, \textit{ESR1}, \textit{ESR2}) regarding recurrence of the disease, we divided patients into four groups in accordance to their age: \(\leq 50\) y.o. (35 patients), 51–60 y.o. (188 patients), 61–70 y.o. (237 patients) and 70\(>\) y.o. (37 patients). Clinical characteristics defining DFS were as follow: “patient.days\_to\_last\_followup” for survival time and “patient.follow\_ups.follow\_up.person\_neoplasm\_cancer\_status” for event. For DFS computation, significance of correlation with survival variable as a method for cutoff point optimization were chosen. Briefly, it is defined as the point with the most significant split. Additionally, hazard ratios (HRs) including 95\% confidence intervals (CI) were calculated [65]. Differences in DFS between favorable and unfavorable groups were presented in form of Kaplan—Meier plots with \(p\)—values calculated (log—rank test, \(p < 0.05\)).

\textbf{Multiple Factor Analysis (MFA)}

We performed dimensional grouping through MFA of PRAD patients according to sets of variables in order to determine the relevance of patients’ age, Gleason score and their association with hormone receptors (\textit{AR}, \textit{ESR1}, \textit{ESR2}), and EMT marker genes. Primarily, 43 genes
known as markers of epithelial-to-mesenchymal transition have been selected from the literature (Table 2) [15–17].

The MFA was conducted in four variants according to the following parameters: 1) partitioning regarding the age groups and combined effect of expression of hormone receptors (AR, ESR1, ESR2) as well as Gleason score (supplementary variable); 2) partitioning regarding the age groups and combined effect of 43 EMT marker genes as well as Gleason score (supplementary variable); 3) partitioning regarding the age groups and combined effect of epithelial/mesenchymal state markers; 4) partitioning regarding the Gleason score and EMT marker genes. The MFA was applied using packages: FactoMineR and factoextra [66] within R environment [67].

Hierarchical clustering

Simultaneously to MFA, we performed hierarchical clustering to examine differences in the expression of particular genes. Clustering was conducted using gplots, NMF and RColorBrewer R packages with pairwise distance measure based on Pearson correlation and complete agglomeration method.

We next cross-validate our findings with alternative prostate cancer study. Due to the lack of RNASeq data resources we chose microarray data from Prostate Adenocarcinoma (MSKCC, Cancer Cell 2010) study which is available in cBioPortal. The clinical parameter not include age information, nevertheless we could perform hierarchical clustering analysis using Gleason score information. To determine the relevance of patients Gleason score and its association with EMT marker genes we divided patients into four groups according to their

Table 5. Clinical characteristics of PRAD cohort with specification by age groups.

| Characteristics          | <50  | 51–60 | 61–70 | 70+ |
|--------------------------|------|-------|-------|-----|
| Age at diagnosis         | total| total | total | total|
| median (range)           | 48 (41–50) | 56 (51–60) | 65 (61–70) | 72 (70–78) |
| Pre-operative PSA median (range) | 6.8 (0.8–107) | 7.6 (1.7–96.4) | 7.35 (0.7–87) | 9.45 (1.7–45) |
| Gleason score            | 2+4  | -     | -     | -   |
|                          | 3+3  | 7     | 23    | 11  |
|                          | 3+4  | 13    | 63    | 60  |
|                          | 4+3  | 6     | 33    | 57  |
|                          | 8>   | 9     | 69    | 109 |
| Tumor cellularity (pathology) | <20% | 1     | 6     | 5   |
|                          | 21–40% | 4     | 8     | 12  |
|                          | 41–60% | 9     | 50    | 84  |
|                          | 61–80% | 12    | 88    | 99  |
|                          | 81–100% | 8     | 29    | 31  |
|                          | NA   | 1     | 7     | 6   |
| PSA recurrence           | yes  | 3     | 21    | 34  |
|                          | no   | 27    | 141   | 174 |
|                          | NA   | 5     | 26    | 29  |

https://doi.org/10.1371/journal.pone.0188842.t005
Gleason score: Gleason 6 (41 patients), Gleason 7 (76 patients), Gleason 8 (11 patients), Gleason 9 (11 patients).

Summary of mutation significance in prostate cancer

Additionally, we analyzed PRAD patients regarding mutations using cBioPortal (http://www.cbioportal.org/) tools. The results have been validated with COSMIC database (Catalogue of somatic mutations in cancer; http://cancer.sanger.ac.uk/cosmic).

Supporting information

S1 Fig. Kaplan-Meier curves for DFS analysis. Panels A-D show AR in groups of age ≤50, 51–60, 61–70, 70> years old, respectively; panels E-H show ESR1 in groups of age ≤50, 51–60, 61–70, 70> years old, respectively; panels I-L show ESR2 in groups of age ≤50, 51–60, 61–70, 70> years old, respectively.

S2 Fig. Characteristics of PRAD patients according to expression of EMT markers and age groups. The expression of EMT markers indicates partition of PRAD cases into patients age (A), however no associations in Gleason score (B). The projections along Dim2 show significant contribution of EMT in distinct partitioning of patients of age ≤50 years old (C). The grouping results from opposite profiles of expression of particular EMT markers in the youngest vs the oldest patients: heightened expression of CDH1, CTNNB1, MMP3, KRT5, SMAD3 with simultaneous lowered expression of KRT18, KRT19, VIM, MMP2, COL4A1, CDH11, CDH2, ITGA5 (D).

S3 Fig. Prostate tumors diagnosed at age ≤50 and 70> years old show opposite characteristics regarding expression of epithelial vs mesenchymal state markers. The expression of epithelial (A) vs mesenchymal (B) state markers in separate partitions PRAD patients oppositely. The projections representing contribution of epithelial (C) and mesenchymal (D) state markers along the dimensions indicate significant shift in the EMT model in the age groups, especially in the youngest and the oldest men. In addition, the shift towards more aggressive mesenchymal character of the tumor is observable in the contrasting expression of particular genes involved in the EMT (E) epithelial state markers, (F) mesenchymal state markers).

S4 Fig. Expression of particular EMT markers changes with Gleason score in patients from Prostate Adenocarcinoma (MSKCC, Cancer Cell 2010) cohort.

Acknowledgments

We acknowledge Wojciech Kuncman for substantial support during writing the publication.

Author Contributions

Conceptualization: Andrzej K. Bednarek.
Funding acquisition: Andrzej K. Bednarek.
Investigation: Dorota Jędręszka, Magdalena Orzechowska.
Methodology: Dorota Jędręszka, Magdalena Orzechowska.
**Supervision:** Andrzej K. Bednarek.

**Visualization:** Dorota Jędrzoska, Magdalena Orzechowska.

**Writing – original draft:** Dorota Jędrzoska, Magdalena Orzechowska, Raneem Hamouz, Karolina Gorniak.

**Writing – review & editing:** Raneem Hamouz, Andrzej K. Bednarek.

**References**

1. Torre LA, Siegel RL, Ward EM, Jemal A. Global Cancer Incidence and Mortality Rates and Trends—An Update. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2016 Jan; 25(1):16–27.

2. Salinas CA, Tsodikov A, Ishak-Howard M, Cooney KA. Prostate cancer in young men: an important clinical entity. Nat Rev Urol. 2014 Jun; 11(6):317–23. [https://doi.org/10.1038/nrurol.2014.91 PMID: 24818853]

3. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974 Jan; 111(1):58–64. PMID: 4813554

4. Epstein JJ, Allsbrook WCJ, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2005 Sep; 29(9):1228–42. PMID: 16096414

5. Epstein JJ, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2016 Feb; 40(2):244–52. [https://doi.org/10.1097/PAS.0000000000000530 PMID: 26492179]

6. Pierorazio PM, Walsh PC, Partin AW, Epstein JJ. Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int. 2013 May; 111(5):753–60. [https://doi.org/10.1111/j.1464-410X.2012.11611.x PMID: 23464824]

7. Humphrey PA. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol Off J U S Can Acad Pathol Inc. 2004 Mar; 17(3):292–306.

8. Steinsmit K, Eder S, Schrader AJ, Steinest J. Clinical significance of epithelial-mesenchymal transition. Clin Transl Med. 2014; 3:17. [https://doi.org/10.1186/2001-1326-3-17 PMID: 25050175]

9. Nauseef JT, Henry MD. Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle? Nat Rev Urol. 2011 Jun 21; 8(8):428–39. [https://doi.org/10.1038/nrurol.2011.85 PMID: 21691304]

10. Bastid J. EMT in carcinoma progression and dissemination: facts, unanswered questions, and clinical considerations. Cancer Metastasis Rev. 2012 Jun; 31(1–2):277–83. [https://doi.org/10.1007/s10555-011-9344-6 PMID: 22215472]

11. Hussein S, Satturwar S, Van der Kwast T. Young-age prostate cancer. J Clin Pathol. 2015 Jul; 68(7):511–5. [https://doi.org/10.1136/jclinpath-2015-202993 PMID: 25837493]

12. Yadav N, Heemers HV. Androgen action in the prostate gland. Minerva Urol E Nefrol Ital J Urol Nephrol. 2012 Mar; 64(1):35–49.

13. Lau K-M, To K-F. Importance of Estrogenic Signaling and Its Mediated Receptors in Prostate Cancer. Int J Mol Sci. 2016 Aug 31; 17(9).

14. Orwoll E, Lambert LC, Marshall LM, Phipps K, Blank J, Barrett-Connor E, et al. Testosterone and estradiol among older men. J Clin Endocrinol Metab. 2006 Apr; 91(4):1336–44. [https://doi.org/10.1210/jc.2005-1830 PMID: 16368750]

15. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009 Jun; 119(6):1420–8. [https://doi.org/10.1172/JCI39104 PMID: 19487818]

16. Ye X, Weinberg RA. Epithelial-Mesenchymal Plasticity: A Central Regulator of Cancer Progression. Trends Cell Biol. 2015 Nov; 25(11):675–86. [https://doi.org/10.1016/j.tcb.2015.07.012 PMID: 26437589]

17. Lee K, Nelson CM. New insights into the regulation of epithelial-mesenchymal transition and tissue fibrosis. Int Rev Cell Mol Biol. 2012; 294:171–221. [https://doi.org/10.1016/B978-0-12-394305-7.00004-5 PMID: 22364874]

18. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res. 2002 Feb 15; 62(4):1008–13. PMID: 11861374

19. Lee D. High androgen receptor levels are predictive of decreased survival in prostate cancer. Clin Prostate Cancer. 2003 Jun; 2(1):13–4. PMID: 15046676
20. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytilä E, Isola J, et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 1997 Jan 15; 57(2):314–9. PMID: 9005575

21. Visakorpi T, Hyytilä E, Koivisto P, Tanner M, Keinanen R, Palmberg C, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet. 1995 Apr; 9 (4):401–6. https://doi.org/10.1038/ng0495-401 PMID: 7795646

22. Ricciardiello C, Choong CS, Buchanan G, Vivekanandan S, Neufang P, Stahl J, et al. Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease. The Prostate. 2005 Apr 1; 63(1):19–28. https://doi.org/10.1002/pros.20154 PMID: 15378523

23. Dong P, Jiang L, Liu J, Wu Z, Guo S, Zhang Z, et al. Induction of paclitaxel resistance by ERalpha mediated prohibitin mitochondrial-nuclear shutting. PLoS One. 2013; 8(12):e83519. https://doi.org/10.1371/journal.pone.0083519 PMID: 24376711

24. Corey E, Quinn JE, Emond MJ, Buhler KR, Brown LG, Vessella RL. Inhibition of androgen-independent growth of prostate cancer xenografts by 17beta-estradiol. Clin Cancer Res Off J Am Assoc Cancer Res. 2002 Apr; 8(4):1003–7.

25. Atala A. Re: Estrogen receptor beta upregulates FOXO3a and causes induction of apoptosis through PUMA in prostate cancer. J Urol. 2015 May; 193(5):1725.

26. Dey P, Jonsson P, Hartman J, Williams C, Strom A, Gustafsson J-A. Estrogen receptors beta1 and beta2 have opposing roles in regulating proliferation and bone metastases genes in the prostate cancer cell line PC3. Mol Endocrinol Baltim Md. 2012 Dec; 26(12):1991–2003.

27. Powell E, Shanle E, Brinkman A, Li J, Keles S, Wisinski KB, et al. Identification of estrogen receptor dimer selective ligands reveals growth-inhibitory effects on cells that co-express ERalpha and ERbeta. PLoS One. 2012; 7(2):e30993. https://doi.org/10.1371/journal.pone.0030993 PMID: 22347418

28. Christoforou P, Christopoulos PF, Koutsilieris M. The role of estrogen receptor beta in prostate cancer. Asian J Androl. 2016 Oct; 18(5):704–10. https://doi.org/10.4103/1008-682X.25032955

29. Safarinejad MR, Safarinejad S, Shafiei N, Safarinejad S. Estrogen receptor alpha (rs2234693 and rs9340799), and beta (rs4986938 and rs1256049) genes polymorphism in prostate cancer: evidence for association with risk and histopathological tumor characteristics in Iranian men. Mol Carcinog. 2012 Oct; 51 Suppl 1:E104–117.

30. Ricke WA, McPherson SJ, Bianco JJ, Cunha GR, Wang Y, Risbridger GP. Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling. FASEB J Off Publ Fed Am Soc Exp Biol. 2008 May; 22(5):1512–20.

31. Leav I, Lau KM, Adams JY, McNeal JE, Taplin ME, Wang J, et al. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol. 2001 Jul; 159(1):79–92. PMID: 11438457

32. Lim J, Thiery JP. Epithelial-mesenchymal transitions: insights from development. Dev Camb Engl. 2012 Oct; 139(19):3471–86.

33. Thiery JP, Acolque H, Huang RYJ, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009 Nov 25; 139(5):871–90. https://doi.org/10.1016/j.cell.2009.11.007 PMID: 19945376

34. Peinado H, Portillo F, Cano A. Transcriptional regulation of cadherins during development and carcinogenesis. Int J Dev Biol. 2004; 48(5–6):365–75. https://doi.org/10.1387/ijdb.041794hp PMID: 15349812

35. Battle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J, et al. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol. 2000 Feb; 2(2):84–9. https://doi.org/10.1038/35000034 PMID: 10655587

36. Thiery JP. The saga of adhesion molecules. J Cell Biochem. 1996 Jun 15; 61(4):489–92. https://doi.org/10.1002/(SICI)1097-4644(19960616)61:4<489::AID-JCB1>3.0.CO;2-K PMID: 8806071

37. Umbas R, Schalken JA, Aalders TW, Carter BS, Karthaus HF, Schaafsm a HE, et al. Expression of the estrogen receptor beta in human normal prostate and carcinoma. Cancer Res. 1992 Sep 15; 52(18):5104–9. PMID: 15160677

38. Umbas R, Isaac WB, Bringuier PP, Schaafsm a HE, Karthaus HF, Oosterhoff GO, et al. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res. 1994 Jul 15; 54(14):3929–33. PMID: 7518346

39. Mooney SM, Jolly MK, Levine H, Kulkarni P. Phenotypic plasticity in prostate cancer: role of intrinsically disordered proteins. Asian J Androl. 2016 Oct; 18(5):704–10. https://doi.org/10.4103/1008-682X.183570 PMID: 27427552

40. Jiang Y-G, Luo Y, He D, Li X, Zhang L, Peng T, et al. Role of Wnt/beta-catenin signaling pathway in epithelial-mesenchymal transition of human prostate cancer induced by hypoxia-inducible factor-1alpha. Int J Urol Off J Jpn Urol Assoc. 2007 Nov; 14(11):1034–9.
Profiles of EMT characterize prostate cancer biology

41. Kypta RM, Waxman J. Wnt/beta-catenin signalling in prostate cancer. Nat Rev Urol. 2012 Aug; 9 (8):418–28. https://doi.org/10.1038/nruol.2012.116 PMID: 22710668

42. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science. 2004 Mar 5; 303(5663):1483–7. https://doi.org/10.1126/science.1094291 PMID: 15001769

43. Labbe E, Letamendia A, Attisano L. Association of Smads with lymphoid enhancer binding factor 1/T cell-specific factor mediates cooperative signaling by the transforming growth factor-beta and wnt pathways. Proc Natl Acad Sci U S A. 2000 Jul 18; 97(15):8358–63. https://doi.org/10.1073/pnas.150152697 PMID: 10890911

44. Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology (Philai). 2007 Jun; 39(3):305–18.

45. Saha B, Arase A, Imam SS, Tsao-Wei D, Naritoku WY, Groshen S, et al. Overexpression of E-cadherin and beta-catenin proteins in metastatic prostate cancer cells in bone. The Prostate. 2008 Jan 1; 68 (1):78–84. https://doi.org/10.1002/pros.20670 PMID: 18008331

46. Tomita K, van Bokhoven A, van Leenders GJ, Ruijter ET, Jansen CF, Bussemakers MJ, et al. Cadherin switching in human prostate cancer progression. Cancer Res. 2000 Jul 1; 60(13):3650–4. PMID: 10910081

47. Tran NL, Nagle RB, Cress AE, Heimark RL. N-Cadherin expression in human prostate carcinoma cell lines. An epithelial-mesenchymal transformation mediating adhesion with Stromal cells. Am J Pathol. 1999 Sep; 155(3):787–98. https://doi.org/10.1016/S0002-9440(10)65177-2 PMID: 10487836

48. Bussemakers MJ, Van Bokhoven A, Tomita K, Jansen CF, Schalken JA. Complex cadherin expression in human prostate cancer cells. Int J Cancer. 2000 Feb 1; 85(3):446–50. PMID: 10652439

49. Halbleib JM, Nelson WJ. Cadherins in development: cell adhesion, sorting, and tissue morphogenesis. Genes Dev. 2006 Dec 1; 20(23):3199–214. https://doi.org/10.1101/gad.148680 PMID: 17158740

50. Jaggi M, Johansson SL, Baker JJ, Smith LM, Galich A, Balaji KC. Aberrant expression of E-cadherin and beta-catenin in human prostate cancer. Urol Oncol. 2005 Dec; 23(6):402–6. https://doi.org/10.1016/j.uroonc.2005.03.002 PMID: 16301117

51. Drake JM, Strohbehn G, Bair TB, Moreland JG, Henry MD. ZEB1 enhances transendothelial migration and represses the epithelial phenotype of prostate cancer cells. Mol Biol Cell. 2009 Apr; 20(8):2207–17. https://doi.org/10.1091/mbc.E08-10-1076 PMID: 19225155

52. Graham TR, Zhau HE, Odero-Marah VA, Osunkoya AO, Kimbro KS, Tighiouart M, et al. Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res. 2008 Apr 1; 68(7):2479–88. https://doi.org/10.1158/0008-5472.CAN-07-2559 PMID: 18381457

53. Anose BM, LaGoo L, Schwendinger J. Characterization of androgen regulation of ZEB-1 and PSA in 22RV1 prostate cancer cells. Adv Exp Med Biol. 2008; 617:541–6. https://doi.org/10.1007/978-0-387-69080-3_55 PMID: 18497080

54. Moody SE, Perez D, Pan T, Sarkisian CJ, Portocarrero CP, Stermer CJ, et al. The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell. 2005 Sep; 8(3):197–209. https://doi.org/10.1016/j.ccr.2005.07.009 PMID: 16169465

55. Deep G, Jain AK, Ramteke A, Ting H, Vijendra KC, Gangar SC, et al. SNAI1 is critical for the aggressiveness of prostate cancer cells with low. Mol Cancer. 2014 Feb 24; 13:37. https://doi.org/10.1186/1476-4588-13-37 PMID: 24565133

56. Gualta S, Puig I, Franci G, Garrido M, Dominguez D, Batlle E, et al. Snail induction of epithelial to mesenchymal transition in tumor cells is accompanied by MUC1 repression and ZEB1 expression. J Biol Chem. 2002 Oct 18; 277(42):39209–16. https://doi.org/10.1074/jbc.M206400200 PMID: 12161443

57. Baritaki S, Chapman A, Yeung K, Spandidos DA, Palladino M, Bonavida B. Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RIKIP induction. Oncogene. 2009 Oct 8; 28(40):3573–85. https://doi.org/10.1038/onc.2009.214 PMID: 19633685

58. Deryugina EI, Quigley JP. Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovascularization. Matrix Biol Int Soc Matrix Biol. 2015 Jul; 44:46–94–112.

59. Bjorklund M, Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta. 2005 May 25; 1755(1):37–69. https://doi.org/10.1016/j.bbamcr.2005.03.001 PMID: 15907591

60. Lin DW, Porter M, Montgomery B. Treatment and survival outcomes in young men diagnosed with prostate cancer: a Population-based Cohort Study. Cancer. 2009 Jul 1; 115(13):2863–71. https://doi.org/10.1002/cncr.24324 PMID: 19466697

61. Merrill RM, Bird JS. Effect of young age on prostate cancer survival: a population-based assessment (United States). Cancer Causes Control CCC. 2002 Jun; 13(5):435–43. PMID: 12146848
62. Huang T-H, Kuo J-Y, Huang Y-H, Chung H-J, Huang WJS, Wu HHH, et al. Prostate cancer in young adults—Seventeen-year clinical experience of a single center. J Chin Med Assoc JCMA. 2017 Jan; 80(1):39–43. https://doi.org/10.1016/j.jcma.2016.10.004 PMID: 27914715

63. Milonas D, Venclovas Z, Gudinaviciene I, Zviniene K, Matjosaitis AJ. Long-Term Oncological Outcomes for Young Men Undergoing Radical Prostatectomy for Localized Prostate Cancer. BioMed Res Int. 2017; 2017:9858923. https://doi.org/10.1155/2017/9858923 PMID: 28299340

64. Cancer Genome Atlas Research Network. The Molecular Taxonomy of Primary Prostate Cancer. Cell. 2015 Nov 5; 163(4):1011–25. https://doi.org/10.1016/j.cell.2015.10.025 PMID: 26544944

65. Budczies J, Klauschen F, Sinn BV, Gyorffy B, Schmitt WD, Darb-Esfahani S, et al. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PloS One. 2012; 7(12):e51862. https://doi.org/10.1371/journal.pone.0051862 PMID: 23251644

66. Lê S, Josse J, Husson F. FactoMineR: An R package for multivariate analysis. J Stat Softw. 2008; 25(1):1–18.

67. Team RC. R: A language and environment for statistical computing. R Found Stat Comput Austria. 2017;